Case report: failure under azithromycin treatment in a case of bacteremia due to Salmonella enterica Paratyphi A
Authors:
- Tetsuro KobayashiTKTetsuro Kobayashi
- Kayoko HayakawaKHKayoko Hayakawa
- Momoko MawatariMMMomoko Mawatari
- Kazuhisa MezakiKMKazuhisa Mezaki
- Nozomi TakeshitaNTNozomi Takeshita
- Satoshi KutsunaSKSatoshi Kutsuna
- Yoshihiro FujiyaYFYoshihiro Fujiya
- Shuzo KanagawaSKShuzo Kanagawa
- Norio OhmagariNONorio Ohmagari
- Yasuyuki KatoYKYasuyuki Kato
- Masatomo MoritaMMMasatomo Morita
Open Access
- 20 July 2014
- journal article
- case report
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 404
Abstract
Limited information is available regarding the clinical efficacy of azithromycin for the treatment of enteric fever due to fluoroquinolone-resistant Salmonella Typhi and Salmonella Paratyphi among travelers returning to their home countries. We report a case of a 52-year-old Japanese man who returned from India, who developed a fever of 39°C with no accompanying symptoms 10 days after returning to Japan from a 1-month business trip to Delhi, India. His blood culture results were positive for Salmonella Paratyphi A. He was treated with 14 days of ceftriaxone, after which he remained afebrile for 18 days before his body temperature again rose to 39°C with no apparent symptoms. He was then empirically given 500 mg of azithromycin, but experienced clinical and microbiological failure of azithromycin treatment for enteric fever due to Salmonella Paratyphi A. However, the minimum inhibitory concentration (MIC) of azithromycin was not elevated (8 mg/L). He was again given ceftriaxone for 14 days with no signs of recurrence during the follow-up. There are limited data available for the treatment of enteric fever using azithromycin in travelers from developed countries who are not immune to the disease, and thus, careful follow-up is necessary. In our case, the low azithromycin dose might have contributed the treatment failure. Additional clinical data are needed to determine the rate of success, MIC, and contributing factors for success and/or failure of azithromycin treatment for both Salmonella Typhi and Salmonella Paratyphi infections.Keywords
This publication has 18 references indexed in Scilit:
- Failure of oral antibiotic therapy, including azithromycin, in the treatment of a recurrent breast abscess caused bySalmonella entericaserotype Paratyphi APathogens and Global Health, 2012
- In Vitro Susceptibility Testing of Fluoroquinolone Activity Against Salmonella: Recent Changes to CLSI StandardsClinical Infectious Diseases, 2012
- Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)Cochrane Database of Systematic Reviews, 2011
- First Report of Salmonella enterica Serotype Paratyphi A Azithromycin Resistance Leading to Treatment FailureJournal of Clinical Microbiology, 2010
- A Multi-Center Randomised Controlled Trial of Gatifloxacin versus Azithromycin for the Treatment of Uncomplicated Typhoid Fever in Children and Adults in VietnamPLOS ONE, 2008
- Alternatives to Ciprofloxacin Use for Enteric Fever, United KingdomEmerging Infectious Diseases, 2008
- In vitro activity of azithromycin, newer quinolones and cephalosporins in ciprofloxacin-resistant Salmonella causing enteric feverJournal of Medical Microbiology, 2007
- Randomized Controlled Comparison of Ofloxacin, Azithromycin, and an Ofloxacin-Azithromycin Combination for Treatment of Multidrug-Resistant and Nalidixic Acid-Resistant Typhoid FeverAntimicrobial Agents and Chemotherapy, 2007
- The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspensionJournal of Antimicrobial Chemotherapy, 1996
- In-vitro concentration of azithromycin in human phagocytic cellsJournal of Antimicrobial Chemotherapy, 1993